CN103732612B - Notch通路信号转导抑制剂化合物 - Google Patents
Notch通路信号转导抑制剂化合物 Download PDFInfo
- Publication number
- CN103732612B CN103732612B CN201280037471.9A CN201280037471A CN103732612B CN 103732612 B CN103732612 B CN 103732612B CN 201280037471 A CN201280037471 A CN 201280037471A CN 103732612 B CN103732612 B CN 103732612B
- Authority
- CN
- China
- Prior art keywords
- cancer
- leukemia
- pharmaceutically acceptable
- compound
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YMZHJBSLZPBJPW-UHFFFAOYSA-N CC(C)(CCOCCN(c(nccc1)c1-c1c(C2NO)cccc1)C2=C)SC Chemical compound CC(C)(CCOCCN(c(nccc1)c1-c1c(C2NO)cccc1)C2=C)SC YMZHJBSLZPBJPW-UHFFFAOYSA-N 0.000 description 1
- SXLWAOQGXQUHOP-UHFFFAOYSA-N CC1(C)OS(c2ccccc2CC(OC)=O)OC1(C)C Chemical compound CC1(C)OS(c2ccccc2CC(OC)=O)OC1(C)C SXLWAOQGXQUHOP-UHFFFAOYSA-N 0.000 description 1
- YCBAQKQAINQRFW-UGSOOPFHSA-N C[C@@H](C(N[C@@H](c(cccc1)c1-c1c(N2CCO)nccc1)C2=O)=O)NC(CCC(F)(F)F)=O Chemical compound C[C@@H](C(N[C@@H](c(cccc1)c1-c1c(N2CCO)nccc1)C2=O)=O)NC(CCC(F)(F)F)=O YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US61/512016 | 2011-07-27 | ||
| US201161560486P | 2011-11-16 | 2011-11-16 | |
| US61/560486 | 2011-11-16 | ||
| PCT/US2012/047100 WO2013016081A1 (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103732612A CN103732612A (zh) | 2014-04-16 |
| CN103732612B true CN103732612B (zh) | 2015-09-23 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280037471.9A Active CN103732612B (zh) | 2011-07-27 | 2012-07-18 | Notch通路信号转导抑制剂化合物 |
Country Status (36)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014110506A2 (en) * | 2013-01-14 | 2014-07-17 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JO3491B1 (ar) * | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| EP3442528B1 (en) * | 2016-04-12 | 2021-05-26 | Eli Lilly and Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer |
| JP6911047B2 (ja) * | 2016-04-12 | 2021-07-28 | イーライ リリー アンド カンパニー | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 |
| JP7194022B2 (ja) | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| SG11201901325UA (en) * | 2016-08-31 | 2019-03-28 | Lilly Co Eli | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| JP7208137B2 (ja) | 2016-12-09 | 2023-01-18 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物および方法 |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| MX2020004568A (es) * | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
| KR20210005714A (ko) * | 2018-05-06 | 2021-01-14 | 아얄라 파마큐티컬즈 아이엔씨. | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 |
| CA3114113A1 (en) | 2018-10-02 | 2020-04-09 | Frequency Therapeutics, Inc. | Pharmaceutical compositions and methods related to otic therapeutic agents |
| US20220175776A1 (en) | 2019-04-08 | 2022-06-09 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
| TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998028268A2 (en) * | 1996-12-23 | 1998-07-02 | Elan Pharmaceuticals, Inc. | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS |
| WO2011060051A1 (en) * | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002518481A (ja) | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物 |
| WO1999067221A1 (en) * | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| EP1592684B1 (en) | 2003-02-04 | 2008-07-30 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
| KR100838852B1 (ko) | 2003-09-09 | 2008-06-16 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| SI1673347T1 (sl) | 2003-10-06 | 2015-10-30 | F. Hoffmann - La Roche Ag | Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze |
| ES2398531T3 (es) | 2006-03-27 | 2013-03-20 | F. Hoffmann-La Roche Ag | Derivados de malonamida como inhibidores de gamma secretasa |
| KR101150574B1 (ko) * | 2007-02-02 | 2012-05-30 | 에프. 호프만-라 로슈 아게 | 6-옥소-6,7-다이하이드로-5ｈ-다이벤조［ｂ,ｄ］아제핀-7-일 유도체 |
| MA33076B1 (fr) | 2008-01-11 | 2012-03-01 | Hoffmann La Roche | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer |
-
2012
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/en not_active Ceased
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active Active
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en not_active Ceased
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 RS RS20150496A patent/RS54135B1/sr unknown
- 2012-07-18 CA CA2841178A patent/CA2841178C/en active Active
- 2012-07-18 PH PH1/2014/500215A patent/PH12014500215B1/en unknown
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/en active Active
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 HR HRP20150771TT patent/HRP20150771T1/hr unknown
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
-
2015
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998028268A2 (en) * | 1996-12-23 | 1998-07-02 | Elan Pharmaceuticals, Inc. | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS |
| WO2011060051A1 (en) * | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103732612B (zh) | Notch通路信号转导抑制剂化合物 | |
| JP6412278B2 (ja) | 平滑筋肉腫の標的治療 | |
| JP2025512920A (ja) | ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製 | |
| WO2018228474A1 (zh) | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 | |
| CN118684666A (zh) | Kif18a抑制剂及其用途 | |
| EP4010343B1 (en) | 7,8-dihydro-4h-pyrazolo[4,3-c]azepine-6-one compounds | |
| NZ618891B2 (en) | Notch pathway signaling inhibitor compound | |
| HK1194086B (en) | Notch pathway signaling inhibitor compound | |
| WO2019170086A1 (zh) | 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用 | |
| HK1251166B (en) | Targeted treatment of leiomyosarcoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |